Clinitech Laboratory promoter Jagdish Umakant Nayak has acquired additional equity shares of the company through open market purchases, as disclosed in a regulatory filing dated March 20, 2026. The acquisition was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011.

Share Acquisition Details

The promoter acquired a total of 4,800 equity shares through open market transactions conducted over two consecutive days. The acquisition schedule was structured as follows:

Shareholding Pattern Changes

The acquisition resulted in an increase in the promoter group's overall shareholding in Clinitech Laboratory Limited. The shareholding pattern before and after the transaction shows the following changes:

Promoter Group Structure

Jagdish Umakant Nayak serves as the promoter and managing director of the company with DIN 00646672. The promoter group includes several persons acting in concert (PACs):

• Mrs. Jyoti Jagdish Nayak
• Mr. Ashutosh Jagdish Nayak
• Ms. Ananya Jagdish Nayak
• Mr. Anant Umakant Nayak
• Mr. Siddhesh Anant Nayak
• Ms. Eshwari Anant Nayak

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations governing substantial acquisition of shares. The company's shares are listed on the Bombay Stock Exchange Limited (BSE) under the symbol CTLLAB with scrip code 544220. The acquired shares are equity shares carrying voting rights, and no encumbrances or convertible securities were involved in this transaction.

The promoter's PAN number is AAVPN2102P, and the acquisition was conducted through standard open market purchases without any special arrangements or preferential allotments.

Clinitech laboratory has disclosed another significant share acquisition by its promoter under SEBI regulations. Jagdish Umakant Nayak, who serves as the company's promoter and Managing Director, purchased 6,000 equity shares through open market transactions on March 12-13, 2026, marking his third consecutive acquisition within a week.

Latest Acquisition Details

The recent share purchase was conducted through open market operations over two days, with 2,400 shares acquired on March 12, 2026, and 3,600 shares on March 13, 2026. The transaction was disclosed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011.

Updated Shareholding Position

The latest acquisition resulted in a significant increase in the promoter's shareholding percentage. Before this transaction, Nayak held 7,05,700 shares representing 30.92% of the total voting capital. Post-acquisition, his holding increased to 7,11,700 shares, representing 31.18% of the company's total voting capital.

Cumulative Recent Acquisitions

Combining all recent transactions, Nayak has acquired a total of 18,000 shares (3,600 + 8,400 + 6,000) over multiple days in March 2026. His overall shareholding has increased from the initial 30.39% to 31.18%, representing a cumulative increase of 0.79%.

Regulatory Compliance

The disclosure was submitted to both Clinitech Laboratory Limited and the Bombay Stock Exchange Limited (BSE), where the company's shares are listed. The company's total equity share capital remained unchanged at 22,82,400 shares following all transactions.

Nayak, who holds the position of Managing Director with DIN 00646672, is based in Navi Mumbai, Maharashtra. These systematic acquisitions represent a continued increase in promoter shareholding through market purchases, further strengthening his stake in the laboratory services company.